Equities Analysts Set Expectations for CNTX Q2 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Analysts at William Blair issued their Q2 2026 EPS estimates for shares of Context Therapeutics in a report released on Tuesday, April 29th. William Blair analyst M. Phipps expects that the company will earn ($0.09) per share for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.51) per share. William Blair also issued estimates for Context Therapeutics' Q4 2026 earnings at ($0.07) EPS.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01.

A number of other research firms also recently issued reports on CNTX. JMP Securities began coverage on Context Therapeutics in a research report on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price target on the stock. D. Boral Capital restated a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Tuesday, April 29th. Citizens Jmp upgraded shares of Context Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $5.00 price objective on shares of Context Therapeutics in a research note on Friday, March 21st. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $6.17.

Context Therapeutics Stock Down 5.8 %

CNTX stock traded down $0.05 during trading on Thursday, hitting $0.79. The company had a trading volume of 69,355 shares, compared to its average volume of 298,241. The firm has a market capitalization of $70.87 million, a P/E ratio of -0.86 and a beta of 2.11. Context Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.75. The company has a 50 day simple moving average of $0.78 and a 200-day simple moving average of $1.15.

Institutional Trading of Context Therapeutics

A number of institutional investors have recently made changes to their positions in the business. State Street Corp raised its stake in Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company's stock valued at $219,000 after buying an additional 19,800 shares during the last quarter. Clear Harbor Asset Management LLC increased its holdings in shares of Context Therapeutics by 60.6% during the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock valued at $61,000 after acquiring an additional 21,804 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Context Therapeutics in the 4th quarter valued at approximately $29,000. Citadel Advisors LLC acquired a new stake in Context Therapeutics in the 4th quarter worth approximately $31,000. Finally, Millennium Management LLC increased its stake in Context Therapeutics by 24.2% during the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company's stock valued at $188,000 after purchasing an additional 34,835 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company's stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.